HBOT Conversations:
Tom Fox (Part 1)
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years, and has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. Tom is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita-RTP team in 2022 as the Safety Director, and is joining us in a 2-part series to discuss the history of Hyperbaric Oxygen Therapy and dive into his personal experience healing patients with HBOT.
Watch the Podcast
We appreciate HBOT historian, Tom Fox, returning to HBOT News to dive in deeper to the history of Hyperbarics, which we can date back to the 1660s!
Tom explains that in the 1830s, the first clinical use of hyperbarics was used and introduced, this revived Nathaniel Henshaw’s concept of Hyperbaric treatments. Nathaniel Henshaw, a clergyman, built a sealed chamber in 1662. Henshaw believed that the application of higher pressure (hyperbaria) was good to treat acute conditions, and that lower pressure (hypobaria) would be better to treat chronic diseases.

1662, Henshaw’s “Domicilium” hyperbaric chamber
This is an interesting fact, because now we’re learning that the cyclic use of hyperbaria (or relative hyperbaria) and hypobaria is very intriguing in what it’s doing from the standpoint of physiology. Tom mentions Dr. Efrati and his group of researchers have been at the forefront of looking at this, and are doing a phenominal job of conducting the hyperbaric studies and getting the hyperbaric education out there. There’s been very limited commitment to do this, he commends Dr. Efrati and his group at Tel Aviv for all they do for the HBOT industry. What you will witness throughout the history of hyperbarics is that they’ve used slightly pressurized room air, and that’s important to know because the slightly pressurized room air has consistently been assumed not to have any effect. It’s even offered up as a control in many of the studies, like the placebo. But the problem is when the placebo helps and the treatment helps, it’s easy to say that the reason both groups are getting better is because of the “participation effect”, or it being “in their heads”. And Dr. Efrati is bringing all this to light. This information is also changing the way the HBOT industry looks at the application of air breaks within the protocols. The use of air breaks was thought to fight oxygen toxicity, but now it’s used to establish a relative hypoxia without going into hypoxic conditions. Host di Girolamo then breaks all of that information down for the viewer to better understand…
So to paraphrase that, you’re breathing pure oxygen and also now you’re breathing air, your body says, ‘oh, oxygen’s depleting, you’re suffocating.’ All these mechanisms occur in your physiology, and then the body’s like, ‘Oh, no, everything’s okay. We have plenty of oxygen.’ So that five minute air break triggers that, and then he’s doing it, I think, three or four times in a 90 minute treatment and it ends up being therapeutic.
Continuing down the timeline of HBOT and fascinating discoveries in the 1800s, Tom Fox brings up a series of articles, Lectures on The Compressed Air Bath and its uses in the treatment of disease, that appeared in the British Medical Journal, dated April 18th, 1885 by a doctor, Theodore Williams. Tom reads the first paragraph from the first article:
“The use of atmospheric air under different degrees of barometric pressure in the treatment of disease is one of the most important advances in modern medicine. When we consider the simplicity of the agent, the exact method by which it is applied, and the precision with which it can be regulated to the requirements of each individual, we are astonished that in England, this method of treatment has been so little used.” – Theodore Williams
That was almost 150 years ago. Back then they were just taking air and putting you under pressure. Now it’s a breakthrough medical treatment, and it’s still not being used in the manner that it could/should be. Almost 200 years ago we were on the cutting edge of medicine! And today we still have to fight to explain that even slightly pressurized room air has a therapeutic benefit — using pressure for healing purposes has literally been happening since the 1600s.

Apparently, Cunningham had some difficulty justifying it all by scientific standards, and this was a very new concept in US medicine. The world had never seen anything like it! Unfortunately, Cunningham fell victim toa unusual amount of scrutiny, and was eventually shut down with the chamber being sold for scrap metal during World War II.
So many people now see the value in Cunningham’s efforts and what he contributed to the HBOT industry. Finally, his work can be interpreted as vindication of the God-given miracle of oxygen and pressure to heal our bodies and minds.
Guests

Thomas M. Fox, MAS,MS, CHT - Safety Director at Extivita RTP & Research Physiologist for the Hyperbaric Institute for Research and Training
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years. During this time, he has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. He has provided contract hyperbaric services since 1997. Prior to accepting his current position in Quebec, Canada, Mr. Fox served as the Chief of the Atmospherics Branch of the U.S. Army School of Aviation Medicine, Fort Rucker Alabama. In this capacity, he was responsible for hyperbaric/ hypobaric operations and training of US and NATO aviators, flight surgeons and flight medics. Mr. Fox is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita team in 2022 as the Safety Director, helping Extivita to maintain a healthy and safe environment for exceptional patient care.
Subscribe Now, It’s Free!
Recent HBOT News
Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study.
Abstract: New biomarkers are needed to assess the severity of necrotizing soft tissue infection (NSTI) at an early stage and to individualize treatment strategies. We assessed pentraxin-3 (PTX3) as a marker of disease severity and risk of death in patients with NSTI....
Hyperbaric Oxygen and Ginkgo Biloba Extract Ameliorate Cognitive and Memory Impairment via Nuclear Factor Kappa-B Pathway in Rat Model of Alzheimer’s Disease.
Hyperbaric oxygen (HBO) and Ginkgo biloba extract (e.g., EGB 761) were shown to ameliorate cognitive and memory impairment in Alzheimer’s disease (AD). However, the exact mechanism remains elusive. The aim of the present study was to investigate the possible mechanisms of HBO and EGB 761 via the function of nuclear factor kappa-B (NF-κB) pathway. AD rats were induced by injecting β-amyloid 25-35 into the hippocampus. All animals were divided into six groups: Normal, sham, AD model, HBO (2 atmosphere absolute; 60 min/d), EGB 761 (20 mg·kg-1·d-1 ), and HBO/EGB 761 groups. Morris water maze tests were used to assess cognitive, and memory capacities of rats; TdT-mediated dUTP Nick-End Labeling staining and Western blotting were used to analyze apoptosis and NF-κB pathway-related proteins in hippocampus tissues. orris water maze tests revealed that EGB 761 and HBO significantly improved the cognitive and memory ability of AD rats. In addition, the protective effect of combinational therapy (HBO/EGB 761) was superior to either HBO or EGB 761 alone. In line, reduced apoptosis with NF-κB pathway activation was observed in hippocampus neurons treated by HBO and EGB 761. ur results suggested that HBO and EGB 761 improve cognitive and memory capacity in a rat model of AD. The protective effects are associated with the reduced apoptosis with NF-κB pathway activation in hippocampus neurons.
Causative pathogens and antibiotic resistance in diabetic foot infections: A prospective multi-center study.
Abstract: Clinical practice guidelines for the management of diabetic foot infections developed by the Infectious Diseases Society of America (IDSA) are commonly used worldwide. The issue of whether or not these guidelines need to be adjusted for local circumstances,...
